ALK and non-small cell lung carcinoma: Many patients with ALK fusions in NSCLC respond to TKI treatment, but later relapse [23], due to succession of a clone with a mutation in the ALK tyrosine kinase domain or a clone with an alternative MEK/ERK signaling abnormality [24].